To test the idea that IRF8’s role in DLBCL biology may be related to a defective antigen processing/presentation, we first created IRF8 KO models in three murine B cell lymphoma cell lines—A20, 2PK-3, and BCL1 (Fig. 4A). This evidence concerns the gene IRF8 and diffuse large B-cell lymphoma.